Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396939 | 1.00 | ADAMTS4 (0.55) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL29379275 | 1.00 | ADAMTS4 (0.55) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL5172404 | 1.00 | ADAMTS4 (0.55) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL30620144 | 0.93 | ADAMTS4 (0.50) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL38659080 | 0.89 | ADAMTS4 (0.49) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL30011822 | 0.87 | ADAMTS4 (0.46) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| Indole SCHEMBL31299797 | 0.86 | ADAMTS4 (0.45) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL29388323 | 0.86 | SMN1; SMN2 (0.74) | KDM4EMAPTTSHRSMN1; SMN2GAA | |
| SCHEMBL45382 | 0.83 | ALPI (0.54) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E | |
| SCHEMBL4393088 | 0.83 | ALPI (0.54) | ADAMTS4LOXL2MTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117969859-B | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-09-06 | — | — | CN | claimed |
| CN-117969859-A | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-05-03 | — | — | CN | claimed |
| EP-1501503-B1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA SPA (IT) | 2008-12-24 | — | — | EP | claimed |
| EP-1326993-B1 | PRODUCTION OF ALPHA-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | EXCELSYN MOLECULAR DEV LTD (GB) | 2007-05-23 | — | — | EP | claimed |
| US-20050208125-A1 | Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances | POLIFARMA S.P.A. (IT) | 2005-09-22 | — | — | US | claimed |
| EP-1501503-A1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA S.p.A. (IT) | 2005-02-02 | — | — | EP | claimed |
| US-20040053382-A1 | Production of alpha-hydroxy-carboxylic acids using a coupled enzyme system | EXCELSYN MOLECULAR DEVELOPMENT LIMITED (GB) | 2004-03-18 | — | — | US | claimed |
| WO-2003094914-A1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYLPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA S.P.A. (IT) | 2003-11-20 | — | — | WO | claimed |
| EP-1326993-A2 | PRODUCTION OF g(a)-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | PCBU Services, Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002033110-A2 | PRODUCTION OF α-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | PCBU SERVICES, INC. (US) | 2002-04-25 | — | — | WO | claimed |
| US-4190585-A | 2,3-DIHYDRO-2,5-FURAN DICARBOXYLIC ACID, PHENYL HYDRAZINE, SULFURIC ACID | LONZA LTD. (CH) | 1980-02-26 | — | — | US | claimed |
| CN-119812333-A | Dispersing agent composition, pole piece and battery | 深圳市德方创域新能源科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119586585-A | Application of bifidobacterium longum CCFM1218 for relieving intestinal barrier injury of gliadin combined high-fat diet | 江南大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-119421888-A | Mammalian milk-derived peptides having antimicrobial activity | 马楚比尔斯公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118956635-A | Lactobacillus johnsonii for relieving ulcerative colitis and application thereof | 南昌大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2003094914-A1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYLPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA S.P.A. (IT) | 2003-11-20 | — | — | WO | disclosed |
| US-4782020-A | Process for the continuous enzymatic conversion of alpha-hydrocarboxylic acids into the corresponding optically active alpha-aminocarboxylic acids | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1988-11-01 | — | — | US | disclosed |
| US-4190585-A | 2,3-DIHYDRO-2,5-FURAN DICARBOXYLIC ACID, PHENYL HYDRAZINE, SULFURIC ACID | LONZA LTD. (CH) | 1980-02-26 | — | — | US | disclosed |
| US-4190585-A | 2,3-DIHYDRO-2,5-FURAN DICARBOXYLIC ACID, PHENYL HYDRAZINE, SULFURIC ACID | LONZA LTD. (CH) | 1980-02-26 | — | — | US | disclosed |
| US-4190585-A | 2,3-DIHYDRO-2,5-FURAN DICARBOXYLIC ACID, PHENYL HYDRAZINE, SULFURIC ACID | LONZA LTD. (CH) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050208125-A1 | Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances | NLN, PYGB, MAPT | ADAMTS4 2228/4885LOXL2 3938/4885MTNR1A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.